StreetInsider.com News Articles

GRAIL, Inc. (GRAL) PT Raised to $150 at Canaccord

Mon, 28 Sep 2026 06:41:02 -0400

(Updated - September 28, 2026 6:41 AM EDT)

Canaccord analyst Kyle Mikson raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $150.00 (from $80.00) while maintaining a Buy rating.

The analyst commented: "We reiterate our BUY rating on GRAIL (GRAL) shares and increase our price target to $150 from $80. Our price target raise is driven by increased revenue estimates throughout our 10-year DCF model following our recent constructive discussion with experts. On Friday, September 25, we hosted a virtual webcast of two key opinion leaders (KOLs) to discuss the recent FDA Advisory Committee (AdCom) meeting (9/23) for GRAIL's Galleri multi-cancer

GRAIL, Inc. (GRAL) PT Raised to $150 at Canaccord

Mon, 28 Sep 2026 06:41:02 -0400

(Updated - September 28, 2026 6:41 AM EDT)

Canaccord analyst Kyle Mikson raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $150.00 (from $80.00) while maintaining a Buy rating.

GRAIL, Inc. (GRAL) PT Raised to $100 at Mizuho

Fri, 25 Sep 2026 06:44:56 -0400

(Updated - September 25, 2026 6:44 AM EDT)

Mizuho analyst Bradley Bowers raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $100.00 (from $65.00) while maintaining a Neutral rating.

The analyst commented: "Ultimately what matters for GRAL out of the 9/23 Advisory Committee (AdComm) are votes on the final three questions asking whether Galleri is Safe for patients, Effective for use, and whether the benefits of using Galleri outweigh the risks. The votes were that Galleri is Safe (10 votes Yes to 0), Effective (6 yes 4 no), and the benefits outweigh the risks (7 yes, 2 no, 1 abstain). Overall

GRAIL, Inc. (GRAL) PT Raised to $100 at Mizuho

Fri, 25 Sep 2026 06:44:56 -0400

(Updated - September 25, 2026 6:44 AM EDT)

Mizuho analyst Bradley Bowers raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $100.00 (from $65.00) while maintaining a Neutral rating.

Canaccord Reiterates Buy Rating on GRAIL, Inc. (GRAL)

Thu, 24 Sep 2026 05:57:53 -0400

Canaccord analyst Kyle Mikson reiterated a Buy rating and $80.00 price target on GRAIL, Inc. (NASDAQ: GRAL)

The analyst comments "We reiterate our BUY rating on GRAIL (GRAL) shares and maintain our price target at $80 (we will review our estimates and DCF model assumptions in the near term). We remain bullish on GRAL shares, as the AdCom meeting for the company's Galleri test went generally better than we expected, with the panel voting in support of approval (while noting the test should not be used to replace guideline-recommended single-cancer screening options). On Wednesday, September 23, the FDA Molecular and Clinical

FDA advisory panel votes to support GRAIL's multi-cancer detection test

Thu, 24 Sep 2026 05:56:51 -0400

An FDA advisory committee voted in favor of approving GRAIL, Inc.'s (NASDAQ: GRAL) Galleri multi-cancer early detection (MCED) test, the company announced Sept. 23, 2026.

The Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee cast three separate votes on the Galleri test's safety, effectiveness, and overall benefit-risk profile for screening adults aged 50 and older for multiple cancer types. The 10 voting members voted seven to two, with one abstention, that the benefits of Galleri outweigh its risks, unanimously in support of its safety, and six to four in support of its effectiveness.

The Galleri test is designed

FDA advisory panel votes to support GRAIL's multi-cancer detection test

Thu, 24 Sep 2026 05:56:51 -0400

An FDA advisory committee voted in favor of approving GRAIL, Inc.'s (NASDAQ: GRAL) Galleri multi-cancer early detection (MCED) test, the company announced Sept. 23, 2026.

The Galleri test is designed

FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test

Wed, 23 Sep 2026 18:17:00 -0400

SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee (the Committee) of the U.S. Food and Drug Administration (FDA) for the approval of the Premarket Approval (PMA) application of the Galleri^® multi-cancer early detection test

FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test

Wed, 23 Sep 2026 18:17:00 -0400

Form 4 GRAIL, Inc. For: Sep 21 Filed by: Ofman Joshua J.

Wed, 23 Sep 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260923/27097128.html

Form 4 GRAIL, Inc. For: Sep 21 Filed by: Freidin Aaron

Wed, 23 Sep 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260923/27097130.html

GRAIL, Inc. (GRAL) PT Raised to $118 at Baird

Tue, 22 Sep 2026 07:23:32 -0400

Baird analyst Catherine Schulte raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $118.00 (from $96.00) while maintaining a Outperform rating.

Form 144 GRAIL, Inc. Filed by: Ofman Joshua J.

Mon, 21 Sep 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260921/27085737.html

RBC Capital Starts GRAIL, Inc. (GRAL) at Sector Perform

Thu, 17 Sep 2026 02:56:52 -0400

RBC Capital analyst Dan Leonard initiates coverage on GRAIL, Inc. (NASDAQ: GRAL) with a Sector Perform rating and a price target of $84.00.

The analyst comments: “We believe the market opportunity for multi-cancer early detection (MCED) tests is substantial -- and GRAIL is a pure play. The upcoming FDA approval for its Galleri test (adcom 9/23) is a compelling catalyst. That said, at the current valuation we have concerns around the slope of the adoption curve, the depth of cash burn, and the distance between today's reimbursement environment and the one that unlocks the addressable market. We could become more constructive

RBC Capital Starts GRAIL, Inc. (GRAL) at Sector Perform

Thu, 17 Sep 2026 02:56:52 -0400

RBC Capital analyst Dan Leonard initiates coverage on GRAIL, Inc. (NASDAQ: GRAL) with a Sector Perform rating and a price target of $84.00.

UBS Assumes GRAIL, Inc. (GRAL) at Buy

Wed, 09 Sep 2026 06:08:38 -0400

UBS analyst Douglas Schenkel assumes coverage on GRAIL, Inc. (NASDAQ: GRAL) with a Buy rating and a price target of $105.00.

For an analyst ratings summary and ratings history on GRAIL, Inc. click here. For more ratings news on GRAIL, Inc. click here.

Shares of GRAIL, Inc. closed at $79.10 yesterday.

GRAIL, Inc. (GRAL) PT Raised to $86 at Baird

Thu, 03 Sep 2026 07:06:00 -0400

Baird analyst Catherine Schulte raised the price target on GRAIL, Inc. (NASDAQ: GRAL) to $86.00 (from $77.00) while maintaining a Outperform rating.

Form 144 GRAIL, Inc. Filed by: Ofman Joshua J.

Thu, 27 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260827/26990396.html

Form 144 GRAIL, Inc. Filed by: Ofman Joshua J.

Thu, 27 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260827/26990396.html

Form 144 GRAIL, Inc. Filed by: Freidin Aaron

Thu, 27 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260827/26990222.html

Form 144 GRAIL, Inc. Filed by: Freidin Aaron

Thu, 27 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260827/26990222.html

Form SCHEDULE 13G/A GRAIL, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26922712.html

Form SCHEDULE 13G/A GRAIL, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26922712.html

FDA panel set to review GRAIL's multi-cancer blood test application

Fri, 07 Aug 2026 11:05:17 -0400

GRAIL, Inc. (Nasdaq: GRAL) announced that the FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026, to review the Premarket Approval (PMA) application for its Galleri multi-cancer early detection (MCED) blood test.

GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.

The Galleri test is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without currently recommended screenings. When a cancer signal is detected, the test is designed to predict the origin

FDA panel set to review GRAIL's multi-cancer blood test application

Fri, 07 Aug 2026 11:05:17 -0400

GRAIL submitted the PMA application to the FDA on Jan. 29, 2026. The FDA designated Galleri as a Breakthrough Device in 2018.